ECL1i
ECL1i is an allosteric, selective CCR2 inhibitor. ECL1i specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis[1].
Product Specifications
CAS Number
1417312-35-6
UNSPSC
12352209
Target
CCR
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Field of Research
Inflammation/Immunology
Smiles
OC([C@@H](CS)NC([C@@H](CCCCN)NC([C@@H](CC(C)C)NC([C@H](NC([C@@H]([C@@H](O)C)NC(CNC([C@H](N)CC(C)C)=O)=O)=O)CC1=CC=CC=C1)=O)=O)=O)=O
Molecular Formula
C36H60N8O9S
Molecular Weight
780.97
References & Citations
[1]Auvynet C, et al. ECL1i, d (LGTFLKC), a novel, small peptide that specifically inhibits CCL2-dependent migration. FASEB J. 2016 Jun;30 (6) :2370-81. doi: 10.1096/fj.201500116. Epub 2016 Mar 15. Erratum in: FASEB J. 2017 Feb;31 (2) :852.
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
No Development Reported
Isoform
CCR2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
